<p>The first <a href="https://www.biospace.com/article/2024-brings-surprising-early-surge-of-biotech-ipos-/" target="_blank" rel="noopener noreferer">surge of IPO activity</a> this year sees Alto Neuroscience, <a href="https://www.biospace.com/article/arrivent-biopharma-seeks-to-potentially-net-over-156m-in-ipo-/" target="_blank" rel="noopener noreferer">ArriVent Biopharma</a>, <a href="https://www.biospace.com/article/cg-oncology-sets-ipo-target-looks-to-raise-up-to-209m/" target="_blank" rel="noopener noreferer">CG Oncology</a>, Kyverna Therapeutics and Metagenomi making announcements. </p>
<p>Lori, Greg and Tyler also discuss <a href="https://www.biospace.com/article/sickle-cell-gene-therapies-seen-as-cost-effective-below-2m-threshold-study/" target="_blank" rel="noopener noreferer">gene therapy pricing</a> including Vertex/CRISPR&#39;s <a href="https://www.biospace.com/article/what-s-next-for-crispr-/" target="_blank" rel="noopener noreferer">Casgevy</a>.</p>

What can biopharma expect from the job market?

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.